Calamos Advisors LLC Boosts Stock Holdings in Madrigal Pharmaceuticals, Inc. $MDGL

Key Points

• Calamos Advisors LLC boosted its stake in Madrigal by 46.4%, acquiring an additional 2,081 shares to hold 6,566 shares valued at $3.824 million, part of a capital base where 98.5% of stock is held by institutional investors.
• Analysts have a consensus rating of "Moderate Buy" with a consensus target price of $685.31, though price targets vary widely (e.g., Goldman $571, Barclays $964), indicating mixed but generally bullish sentiment.
• Madrigal reported an EPS miss (−$2.57 vs. $0.04 expected) despite revenue rising 210.8% to $321.08 million; the stock trades around $512 with a 52-week range of $265–$615 and a market cap of $11.75 billion.

Calamos Advisors LLC boosted its stake in shares of Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL - Free Report) by 46.4% in the 4th quarter, according to its most recent disclosure with the SEC. The institutional investor owned 6,566 shares of the biopharmaceutical company's stock after acquiring an additional 2,081 shares during the period. Calamos Advisors LLC's holdings in Madrigal Pharmaceuticals were worth $3,824,000 at the end of the most recent quarter.

Several other institutional investors also recently bought and sold shares of MDGL. Hsbc Holdings PLC purchased a new position in Madrigal Pharmaceuticals during the second quarter valued at $309,000. Qube Research & Technologies Ltd purchased a new position in Madrigal Pharmaceuticals during the second quarter valued at $1,163,000. Sei Investments Co. grew its stake in Madrigal Pharmaceuticals by 73.6% during the second quarter. Sei Investments Co. now owns 17,542 shares of the biopharmaceutical company's stock valued at $5,309,000 after acquiring an additional 7,438 shares in the last quarter. The Manufacturers Life Insurance Company grew its stake in Madrigal Pharmaceuticals by 2.1% during the second quarter. The Manufacturers Life Insurance Company now owns 23,416 shares of the biopharmaceutical company's stock valued at $7,087,000 after acquiring an additional 471 shares in the last quarter. Finally, Bayesian Capital Management LP purchased a new position in Madrigal Pharmaceuticals during the second quarter valued at $418,000. 98.50% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Several equities analysts recently weighed in on the stock. Weiss Ratings reaffirmed a "sell (d-)" rating on shares of Madrigal Pharmaceuticals in a research note on Tuesday, April 21st. Wolfe Research set a $579.00 price objective on shares of Madrigal Pharmaceuticals in a research report on Tuesday, January 6th. Zacks Research raised shares of Madrigal Pharmaceuticals from a "strong sell" rating to a "hold" rating in a research note on Friday, February 20th. The Goldman Sachs Group reissued a "buy" rating and issued a $571.00 price objective on shares of Madrigal Pharmaceuticals in a research note on Wednesday, January 14th. Finally, Barclays started coverage on shares of Madrigal Pharmaceuticals in a research note on Tuesday, January 27th. They issued an "overweight" rating and a $964.00 price objective for the company. One research analyst has rated the stock with a Strong Buy rating, twelve have assigned a Buy rating, three have assigned a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and a consensus target price of $685.31.

Madrigal Pharmaceuticals Stock Performance

Shares of NASDAQ:MDGL opened at $512.39 on Monday. Madrigal Pharmaceuticals, Inc. has a 52 week low of $265.00 and a 52 week high of $615.00. The stock has a market capitalization of $11.75 billion, a P/E ratio of -39.81 and a beta of -1.00. The firm has a fifty day simple moving average of $479.28 and a two-hundred day simple moving average of $502.84. The company has a quick ratio of 3.77, a current ratio of 4.01 and a debt-to-equity ratio of 0.56.

Madrigal Pharmaceuticals (NASDAQ:MDGL - Get Free Report) last issued its quarterly earnings data on Thursday, February 19th. The biopharmaceutical company reported ($2.57) EPS for the quarter, missing analysts' consensus estimates of $0.04 by ($2.61). Madrigal Pharmaceuticals had a negative return on equity of 43.76% and a negative net margin of 30.08%.The business had revenue of $321.08 million during the quarter, compared to analysts' expectations of $310.36 million. During the same period in the previous year, the business earned ($2.71) earnings per share. The business's quarterly revenue was up 210.8% on a year-over-year basis. On average, analysts expect that Madrigal Pharmaceuticals, Inc. will post -5.22 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other Madrigal Pharmaceuticals news, CFO Mardi Dier sold 1,982 shares of Madrigal Pharmaceuticals stock in a transaction on Friday, March 6th. The shares were sold at an average price of $430.87, for a total value of $853,984.34. Following the completion of the transaction, the chief financial officer directly owned 12,490 shares of the company's stock, valued at $5,381,566.30. This trade represents a 13.70% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this link. Also, General Counsel Shannon T. Kelley sold 360 shares of the firm's stock in a transaction dated Friday, March 6th. The stock was sold at an average price of $431.94, for a total transaction of $155,498.40. Following the completion of the sale, the general counsel owned 12,138 shares of the company's stock, valued at $5,242,887.72. This trade represents a 2.88% decrease in their position. The SEC filing for this sale provides additional information. Over the last ninety days, insiders sold 6,098 shares of company stock worth $2,626,254. Insiders own 21.50% of the company's stock.

Madrigal Pharmaceuticals Profile

Madrigal Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on the development of innovative therapies for cardiovascular, metabolic and liver diseases. The company's pipeline centers on novel, liver-directed agents designed to address significant unmet medical needs, with an emphasis on nonalcoholic steatohepatitis (NASH) and related metabolic disorders.

The lead product candidate, resmetirom (MGL-3196), is an orally administered, selective thyroid hormone receptor-β agonist in Phase 3 development for the treatment of NASH.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.